Effect of listing ciprofloxacin in provincial formularies on hospitalizations for bronchitis and pyelonephritis

Canadian Journal of Clinical Pharmacology

Volumn 5, Issue 3, 1998, Pages 133-137

  LeLorier, Jacques ^a   Derderian, François ^b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b NONE

Author keywords

Bronchitis; Ciprofloxacin; Ecological correlations; Pharmacoeconomics; Pyelonephritis

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN;

ANTIBIOTIC THERAPY; ARTICLE; BRONCHITIS; CANADA; DRUG COST; HOSPITALIZATION; HUMAN; MULTIVARIATE ANALYSIS; OUTPATIENT CARE; PUBLICATION; PYELONEPHRITIS; REGRESSION ANALYSIS;

EID: 0031661171     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Chodosh S, Tuck J, Stottmeier KD, et al. Comparison of ciprofloxacin with ampicillin in acute infectious exacerbations of chronic bronchitis. A double-blind crossover study. Am J Med 1989;87:107S-12S.
2. Chodosh S. Use of quinolones for the treatment of acute exacerbations of chronic bronchitis. Am J Med 1991;91:93S-100S.
3. Fass RJ. Efficacy and safety of oral ciprofloxacin in the treatment of serious respiratory infections. Am J Med 1987;82:202-7.
4. Hooper DC, Wolfson JS. Fluoroquinolone antimicrobial agents. N Engl J Med 1991;324:384-93.
5. Hoogkamp-Korstanje JA, Klein SJ. Treatment of acute exacerbations of chronic bronchitis with ciprofloxacin. Pharm Weekbl Sci 1987;9(Suppl):S60-3.
6. Kosmidis J. A double-blind study of once-daily temafloxacin in the treatment of bacterial lower respiratory tract infections. J Antimicrob Chemother 1991;28(Suppl C):73-9.
7. Quenzer RW, Davis RL, Neidhart MM. Prospective randomized study comparing the efficacy and safety of ciprofloxacin with cefaclor in the treatment of patients with purulent bronchitis. Diagn Microbiol Infect Dis 1990;13:143-8.
8. Schmidt EW, Zimmermann I, Ritzerfeld W, Voss E, Ulmer WT. Controlled prospective study of oral amoxycillin/clavulanate vs ciprofloxacin in acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1989;24(Suppl B):185-93.
9. Bach D, van den Berg-Segers A, Hubner A, van Breukelen G, Cesana M, Pletan Y. Rufloxacin once daily versus ciprofloxacin twice daily in the treatment of patients with acute uncomplicated pyelonephritis. J Urol 1995;154:19-24.
10. Naber KG. Use of quinolones in urinary tract infections and prostatitis. Rev Infect Dis 1989;11(Suppl):S1321-37.
11. Meyrier A, Guibert J. Diagnosis and drug treatment of acute pyelonephritis. Drugs 1992;44:356-67.
12. Stamm WE, Hooton TM. Management of urinary tract infections in adults. N Engl J Med 1993;329:1328-34.
13. Tamblyn R, Lavoie G, Petrella L, Monette J. The use of prescription claims data bases in pharmacoepidemiology research: the accuracy and comprehensiveness of the prescriptions claims database in Quebec. J Clin Epidemiol 1995;48:999-1009.
14. Malcolm E, Downey W, Strand LM, McNutt M, West R. Saskatchewan Health's linkable data bases and pharmacoepidemiology. Post Marketing Surveillance 1993;6:175-264.
15. Box GEP, Jenkins GM. Time Series Analysis Forecasting and Control, 2nd edn. San Francisco: Holden-Day, 1976.
16. SAS Institute Inc. SAS/ETS® User's Guide, Version 6, 2nd edn. Cary: SAS Institute Inc, 1993.
17. McCleary R, Hay RA Jr. Applied Time Series Analysis for the Social Sciences. Beverly Hills: Sage, 1980.
18. Wei WWS. Time Series Analysis. Redwood City: Addison-Wesley, 1990.